CJC-1295 NO DAC CJC-1295 without DAC (Drug Affinity Complex) is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). It’s a modified version of the first 29 amino acids of natural GHRH, designed for enhanced stability and a longer half-life compared to unmodified GHRH. Unlike CJC-1295 with DAC (which has a half-life of ~6-8 days due to albumin binding), the “No DAC” version has a shorter half-life of about 30 minutes to 2 hours, making it suitable for more frequent dosing to mimic natural GH pulses. Key Chemical Details: Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2 (with specific modifications like norleucine substitution). Molecular Formula: C152H252N44O42. Molecular Weight: ~3,369 Da. Developed by ConjuChem Biotechnologies in the early 2000s for research into GH deficiency and anti-aging. Primary Uses and Mechanism CJC-1295 No DAC acts as a GHRH agonist, binding to pituitary GHRH receptors to stimulate pulsatile release of endogenous growth hormone (GH) and subsequently insulin-like growth factor 1 (IGF-1). This leads to: Increased lean muscle mass and fat loss. Improved recovery, sleep quality, and collagen synthesis. Potential benefits for anti-aging, injury repair, and metabolic health. It’s commonly used in research settings or by biohackers/bodybuilders, often stacked with a growth hormone-releasing peptide (GHRP) like Ipamorelin or GHRP-6 for synergistic GH pulses. Evidence comes from preclinical studies (e.g., Teichman et al., 2006, showing 2-10x GH increase) and anecdotal reports, though human clinical trials are limited post-patent issues. Comparison: CJC-1295 Variants Half-Life Dosing Frequency GH Release Profile No DAC ~30 min – 2 hrs 2-3x/day Short, pulsatile With DAC ~6-8 days 1-2x/week Prolonged, steady Dosage and Administration (Research Contexts) Typical Research Dose: 100-200 mcg per subcutaneous injection, 1-3 times daily (e.g., post-workout, bedtime). Stack Example: 100 mcg CJC-1295 No DAC 100 mcg Ipamorelin, 2-3x/day. Reconstituted with bacteriostatic water; store lyophilized at -20°C, reconstituted at 2-8°C. Cycle: 8-12 weeks on, 4 weeks off to avoid pituitary desensitization. Evidence: A 2005 study (Albazali et al.) in healthy males showed 100 mcg IV dose increased GH by 5-10x for 1-2 hours, with IGF-1 elevation over 24 hours. No large RCTs for performance enhancement. Side Effects and Risks Common (mild, transient): Flushing, warmth, or head rush (5-15 min post-injection). Water retention, numbness in extremities. Rare/Serious: Potential insulin resistance with chronic high doses. GH-related risks: carpal tunnel, joint pain, increased cancer risk if predisposed (theoretical, based on GH/IGF-1 axis). Not FDA-approved for human use; sourced as “research chemical” (purity varies; third-party testing advised). Side Effect Frequency Mitigation Injection site reaction Common Rotate sites, sterile technique Fatigue/hunger Moderate Lower dose, time with meals Elevated cortisol/prolactin Rare (if stacked poorly) Avoid high GHRP combos Legality and Availability Status: Research peptide only (not for human consumption in most countries). Banned by WADA for athletes (Class S2.2). Legal to purchase for lab research in the US/EU from vendors like Peptide Sciences or Limitless Life Nootropics. Purity Concerns: HPLC-tested products should be >98%; avoid unverified sources to prevent contaminants like heavy metals. For deeper dives, check PubMed (search “CJC-1295 pharmacokinetics”) or research papers like “Prolonged Stimulation of Growth Hormone by CJC-1295” (J Clin Endocrinol Metab, 2006). Always consult a physician for personal use—I’m not medical advice.
